

In the Drawings:

Please replace original Figure 1 with amended Figure 1. Applicants herewith provide: (1) clean copy of amended FIG. 1, and (2) mark-up copy of amended FIG. 1.

In the Sequence Listing:

Please enter the Sequence Listing into this application.

### **Remarks**

This SECOND PRELIMINARY AMENDMENT is filed in response to a Withdrawal of Previously Sent Notice and Notification of Defective Response mailed July 9, 2007 and is being submitted prior to examination of this application. Please enter this Amendment into the application.

### **In the Drawings**

FIG. 1 has been amended to correct a typographical error in the last line of page 1, codon 7 from the left. Original FIG. 1 incorrectly identified this codon as ACT, whereas the correct codon is ATC. This error and its correction are obvious from the sequence of the 20 kDa hGH-V as shown in FIG. 2, and from the published sequence of this HG variant (Genbank Accession No: AF006060; see page 20 of application as filed).

With this PRELIMINARY AMENDMENT, Applicants enclose: (1) a clean version of page 1 of FIG. 1 as Appendix 1, and (2) a mark-up version of page 1 of FIG. 1 showing the amendment to be made. Applicants herein request the amended page 1 of FIG. 1 be entered into the application.

### **In the Specification**

The specification was objected to as requiring sequence identifiers for each of the proteins disclosed.

The specification has been amended to provide sequence identifiers (SEQ ID NOs) for the proteins and their claimed uses described. Due to the number of insertions into the specification, Applicants herein provide a Substitute Specification, in Clean and Mark-Up versions. The Clean version is attached to this PRELIMINARY AMENDMENT as Appendix 3. The Mark-Up version is attached to this PRELIMINARY AMENDMENT as Appendix 4. Applicants herein request the substitute specification to be entered into the application. The specification Table 1 has been amended in the same fashion as FIG. 1.

### **In the Sequence Listing**

Applicants herewith provide: (1) a paper copy of a Sequence Listing and (2) a diskette containing the Sequence Listing. Applicants state that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

The sequence listing in computer readable form is attached to this PRELIMINARY AMENDMENT as Appendix 5. Applicants herein incorporate the attached sequence listing (paper and compact diskette) by reference in their entirety.

### Amendments to the Claims

Certain claims have been amended to identify the protein and its uses by the sequence identifiers. Additionally, status identifiers have been supplied. Applicants submit that all of the amendments presented are to make explicit, that which was implicit in the claims as originally filed.

A Petition for Extension of Time is provided, along with the required fee. The Commissioner is hereby authorized to charge any deficiencies or credit overpayment to Deposit Account No. 50-4089.

Please note that the docket number for this application has changed. The new docket number is ERNZ-01082US3.

Respectfully submitted,

Date: December 18, 2007

By: 

D. Benjamin Borson, Ph.D.  
Reg. No.: 42,349

Customer No. 66936  
BORSON LAW GROUP, PC  
1320 Willow Pass Road, Suite 490  
Concord, California 94520-5232  
Tel: (925) 395-2060